Abstract |
WEB 2347 is a new hetrazepine which is superior to the previously described paf-antagonists WEB 2086 (apafant) and WEB 2170 (bepafant). This refers to both potency in vitro and in vivo (particularly after oral administration: e.g. the ED50 after oral administration is about 100 times less for WEB 2347 than for WEB 2086 to antagonize paf-induced hypotension in the rat) and duration of action (t1/2 = 41 h in the guinea pig and about 10 h in the rat after p.o. administration). Furthermore the role of paf in active anaphylaxis in vivo, even after repeated microshock, is strengthened.
|
Authors | H O Heuer |
Journal | Journal of lipid mediators
(J Lipid Mediat)
Vol. 4
Issue 1
Pg. 39-44
( 1991)
ISSN: 0921-8319 [Print] Netherlands |
PMID | 1893086
(Publication Type: Journal Article)
|
Chemical References |
- Azepines
- Platelet Activating Factor
- Triazoles
- WEB 2347
- bepafant
|
Topics |
- Administration, Oral
- Anaphylaxis
(physiopathology)
- Animals
- Azepines
(administration & dosage, pharmacology)
- Bronchoconstriction
(drug effects)
- Guinea Pigs
- Hypotension
(physiopathology)
- Immunization
(methods)
- Platelet Activating Factor
(antagonists & inhibitors)
- Platelet Aggregation
(drug effects)
- Rabbits
- Rats
- Rats, Inbred Strains
- Time Factors
- Triazoles
(administration & dosage, pharmacology)
|